NCT02069535View on ClinicalTrials.gov

An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

AVANZ Cupressus

AVANZ Cupressus

Trial Locations (1)

Unknown

Hospital Clinico Universitario San Carlos, Madrid

All Listed Sponsors
lead

ALK-Abelló A/S

INDUSTRY

NCT02069535 - An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy | Biotech Hunter | Biotech Hunter